CHEMDOODLE LICENSE OR EQUAL
ID: 75F40125Q00087Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONFDA OFFICE OF ACQ GRANT SVCSBeltsville, MD, 20705, USA

NAICS

Professional Organizations (813920)

PSC

IT AND TELECOM - DATA CENTER PRODUCTS (HARDWARE AND PERPETUAL LICENSE SOFTWARE) (7C20)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/opp/acdc1a21dd4848b880d03eb0e0cc87e3/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking quotes for a ChemDoodle site license or an equivalent chemical drawing tool through a Total Small Business Set-Aside procurement. The software must be compatible with Windows, Mac, and Linux operating systems and include features such as interactive drawing capabilities, various export and import formats, IUPAC naming functionalities, and integration with Excel for property calculations. This procurement is crucial for providing FDA users with the necessary tools for chemical structure representation and analysis, with the contract set to span from January 21, 2025, to January 20, 2026. Interested vendors should contact Tiffany Hatcher at Tiffany.Hatcher@fda.hhs.gov or call 240-402-1492 for further details.

    Point(s) of Contact
    Tiffany Hatcher
    (240) 402-1492
    Tiffany.Hatcher@fda.hhs.gov
    Files
    Title
    Posted
    RFQ 75F40125Q00087.pdf
    The U.S. Food and Drug Administration (FDA) is soliciting quotes for the ChemDoodle Advanced Software Suite, a chemical drawing tool, through a Total Small Business Set-Aside procurement. The software is intended for all FDA users and must be compatible with Windows, Mac, and Linux operating systems, including onsite maintenance and technical support. Key features required include interactive drawing capabilities, various export and import formats, IUPAC naming functionalities, and integration with Excel for calculating properties of chemical structures. The contract, which is firm-fixed price, spans one year from January 21, 2025, to January 20, 2026, with specific deliverables and maintenance provisions outlined. The FDA emphasizes that the contractor must provide essential support and access to updates during the contract period. The document details the inspection and acceptance criteria, performance evaluation processes, and compliance with electronic invoicing through the Department of Treasury’s Invoice Processing Platform, ensuring adherence to federal regulations and efficiency in payment processing.
    Lifecycle
    Title
    Type
    CHEMDOODLE LICENSE OR EQUAL
    Currently viewing
    Combined Synopsis/Solicitation
    Similar Opportunities
    PRIMO Software Licensing
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide PRIMO Software Licensing and Maintenance Support Services. The procurement involves supplying 21 PRIMO software licenses for a base year, with two additional option years, to ensure the continuous operation of the FDA's CFSAN CAEMS system. This software is crucial for pharmacovigilance and regulatory compliance, enhancing the FDA's capabilities in monitoring food safety. Interested parties must submit their quotes by August 26, 2024, and are encouraged to contact Roosevelt Walker at roosevelt.walker@fda.hhs.gov for further details. The contract will be awarded as a firm-fixed-price purchase order, emphasizing compliance with federal acquisition regulations and accessibility standards.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services to support the development of drug products. The objective of this procurement is to ensure the delivery of high-quality formulated drug products for preclinical, IND-enabling, and clinical studies, which are critical for advancing therapeutic development. This opportunity encompasses a wide range of services, including formulation development, manufacturing under current Good Manufacturing Practices (cGMP), and necessary testing to meet regulatory standards. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can contact Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Access to Outpatient Longitudinal Drug Utilization Data
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide access to outpatient longitudinal drug utilization data through a Sources Sought notice. The primary objective is to acquire existing, HIPAA-compliant data resources that will enhance drug safety evaluations, support post-market surveillance, and inform regulatory decisions, rather than developing new databases. This initiative is crucial for monitoring medication utilization trends, particularly in areas such as opioid surveillance, and aims to improve public health outcomes through rigorous analyses of drug safety data. Interested firms must submit their responses by January 23, 2025, including their business size status and DUNS number, and can direct inquiries to Telisha Wilson at telisha.wilson@fda.hhs.gov.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Solicitation: Tobacco Retailer Inspections - 75F40125R00018
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is soliciting proposals for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to conduct tobacco retailer inspections across multiple regions in the United States. The primary objective of this procurement is to ensure compliance with federal laws regarding the sale and advertising of tobacco products, particularly focusing on preventing youth access to these products. This initiative is critical for enhancing the FDA's enforcement capabilities and protecting public health by reducing tobacco use among minors. Interested contractors should contact Janice Heard at janice.heard@fda.hhs.gov or Brandon Rafus at brandon.rafus@fda.hhs.gov for further details, with the contract period spanning five years and specific funding amounts to be determined for each region.
    FDA Move and Labor Services Recompete
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified certified 8(a) small business firms to provide Move and Labor Services under an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The primary objective is to assist over 14,000 personnel in the National Capital Region with various moving activities, including specialized laboratory and IT relocations, document destruction, and warehouse management. This initiative is crucial for maintaining operational efficiency and secure handling of sensitive materials within the FDA. Interested firms must submit their responses by January 23, 2025, to Sheneil Green at Sheneil.Green@fda.hhs.gov, with further details outlined in the attached Statement of Work.
    Bulk Pharma Group B
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking proposals for the procurement of a range of FDA-approved pharmaceuticals as part of the Bulk Pharma Group B initiative. The contract will require the delivery of specific injectable medications, including Acyclovir Sodium, Doxycycline, Levophed, Meropenem, Sodium Chloride, and sterile water, with quantities detailed in the attached Request for Proposal (RFP). This procurement is critical for maintaining the Strategic National Stockpile, ensuring a reliable supply of essential pharmaceuticals for disaster preparedness and response efforts. Interested vendors must submit their proposals by the specified deadline, and inquiries can be directed to primary contact Terri Reed at terri.reed@hhs.gov or secondary contact Kimberly Golden at kimberly.golden1@hhs.gov.
    Chemistry Analyzer Piccolo Xpress, CLIA Waived (AMBIS 2247161)
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for the procurement of two Piccolo Xpress Chemistry Analyzers as part of a combined synopsis/solicitation. These analyzers are essential for the Vaccine Research Center's ongoing clinical trials in Kenya, requiring compatibility with existing laboratory equipment to ensure data consistency and continuity in research. The Piccolo Xpress is a portable, fully automated clinical chemistry analyzer capable of performing over 30 blood chemistry tests, providing rapid results with minimal user interaction. Interested vendors must submit their quotes by January 17, 2025, at 4:00 PM EST, and can direct inquiries to Rita Davis at rita.davis@nih.gov or Tonia Alexander at talexander@niaid.nih.gov.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotations for a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) related to the procurement of pharmaceutical agents as part of its Uniform Formulary (UF) initiative. This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of newly approved drugs across various therapeutic classes, including neurological agents, antibiotics, oncological agents, and more. The selected pharmaceutical agents will be evaluated by the Pharmacy and Therapeutics (P&T) Committee during meetings scheduled for February 5-6, 2025, with quotes due by January 16, 2025. Interested manufacturers should submit their quotes and any required documentation to the designated contacts, Tracy Banks and Patricia Tyson, at the provided email addresses.
    100-Ton Chiller
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking small businesses capable of providing a new energy-efficient 100-ton chiller for installation at the San Juan District Office in Puerto Rico. The project requires the contractor to ensure seamless integration of the chiller into the existing system while maintaining the operational status of the current chiller as a backup, all without disrupting laboratory operations. This procurement is crucial for enhancing laboratory efficiency and compliance with federal, state, and local regulations. Interested parties must submit their responses by January 21, 2025, to assist the FDA in determining the appropriateness of a small business set-aside, with the project performance period scheduled from February 26, 2025, to February 25, 2026. For further inquiries, contact Yolanda Rankin at yolanda.rankin@fda.hhs.gov or Sheneil Green at Sheneil.Green@fda.hhs.gov.